优化腹腔内化疗的时间,以提高静脉注射的碳白金度
Kohei Tamura1, Natsuka Kimura2, Hideyuki Ohzawa3,4
1Department of Obstetrics and Gynecology, Jichi Medical University, Tochigi 329-0498, Japan.
Cancers
|August 29, 2024
概括
腹腔内帕克利塔塞尔 (IP PTX) 在胃癌 (GC) 患者的腹腔内瘤中增加化疗药物度. 连续的IV药物与IP PTX一起使用可能会改善腹转移 (PMs) 的治疗疗效.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 癌症转移研究 癌症转移研究
背景情况:
- 胃癌 (GC) 与腹转移 (PMs) 尽管有系统化疗,预后不好.
- 内 (IP) 帕克利塔塞尔 (PTX) 与全身疗法相结合显示出治疗GC PMs的潜力.
- 优化药物输送方法对于最大限度地提高治疗疗效至关重要.
研究的目的:
- 评估IP与静脉注射 (IV) 帕克利塔克塞尔 (PTX) 对腹瘤中药物度的影响.
- 为了确定卡博普拉丁 (CBDCA) 与IP PTX一起用于GC PMs的最佳时间.
- 调查提高化学疗法的疗效,以治疗GC与PMs.
主要方法:
- 利用来自人类GC细胞系的腹转移 (PMs) 的GC小鼠模型.
- 通过IP或IV路线给药PTX,然后在PTX后的0,1或4天内给药IV碳金 (CBDCA).
- 在切除的瘤中测量PTX和CBDCA度,使用液体染色学-并联质谱法 (LC-MS/MS).
主要成果:
- 与静脉注射相比,IP PTX 给药导致腹膜瘤中PTX度更高,特别是在0日和1日.
- 在IP PTX给药4天后,CBDCA度比同步IV PTX给药高4天.
- IP PTX的使用被证明可以提高腹膜瘤中随后的CBDCA度.
结论:
- 输入期内给予PTX会增加其在腹瘤中的度.
- 在IP PTX之后,对抗癌药物如CBDCA等进行连续的IV注射可能比同时注射更有效.
- 这种优化的药物输送策略有可能改善GC和PM患者的预后.
关键词:
卡博普拉丁是碳酸盐中的一种.胃癌 胃癌 是一种胃癌.间隔时间 间隔时间 时间表内皮层内化学疗法.静脉注射化疗是一种静脉注射化疗.帕克利塔克塞尔 (paclitaxel) 是一种药物.腹膜转移的发生.更多相关视频
09:02Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
11.9K
09:49Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
Published on: December 2, 2013
10.3K
相关概念视频
01:19One-Compartment Open Model for IV Bolus Administration: General Considerations
173
The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
173
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:25Routes of Drug Administration: Parenteral
1.9K
The administration of drugs via parenteral routes allows for direct drug introduction into the systemic circulation, resulting in high bioavailability because the medication bypasses the harsh conditions of the gastrointestinal tract and hepatic metabolism.
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
1.9K
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
181
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
181
00:59Nonlinear Pharmacokinetics: Drug Elimination for IV Bolus Injection
51
In pharmacokinetics, the elimination rate of a drug following a capacity-limited model is primarily controlled by two parameters: Vmax and KM. These parameters are crucial in how the drug behaves inside the body after administration.
Following the administration of a single intravenous (IV) bolus injection, we can determine the concentration of the drug in the plasma at any given time. This calculation is achieved using a specific equation that integrates the values of Vmax and KM.
We can also...
Following the administration of a single intravenous (IV) bolus injection, we can determine the concentration of the drug in the plasma at any given time. This calculation is achieved using a specific equation that integrates the values of Vmax and KM.
We can also...
51
01:18Two-Compartment Open Model: IV Bolus Administration
426
The two-compartment model for intravenous (IV) bolus administration illustrates drug distribution in the body, subdividing it into central and peripheral compartments. This model operates on the concept of two-compartment kinetics. The drug's plasma concentration shows a bi-exponential decline following IV bolus administration, signaling the presence of two disposition processes: distribution and elimination.
The disparity between drug input and the sum of drug transfer rates between...
The disparity between drug input and the sum of drug transfer rates between...
426